Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,400
Employees6,400
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,400
Employees6,400

VRTX Key Statistics

Market cap
138.86B
Market cap138.86B
Price-Earnings ratio
31.68
Price-Earnings ratio31.68
Dividend yield
Dividend yield
Average volume
1.04M
Average volume1.04M
High today
$551.40
High today$551.40
Low today
$541.00
Low today$541.00
Open price
$548.69
Open price$548.69
Volume
732.40K
Volume732.40K
52 Week high
$555.69
52 Week high$555.69
52 Week low
$374.17
52 Week low$374.17

Stock Snapshot

The current Vertex Pharmaceuticals(VRTX) stock price is $547.65, with a market capitalization of 138.86B. The stock trades at a price-to-earnings (P/E) ratio of 31.68.

On 2026-09-01, Vertex Pharmaceuticals(VRTX) stock moved within a range of $541.00 to $551.40. With shares now at $547.65, the stock is trading +1.2% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 732.4K, compared to an average daily volume of 1.04M.

The stock's 52-week range extends from a low of $374.17 to a high of $555.69.

The stock's 52-week range extends from a low of $374.17 to a high of $555.69.

VRTX News

TipRanks 7h
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals

Vertex Pharmaceuticals (VRTX) announced the successful completion of the acquisition of Crinetics Pharmaceuticals (CRNX). Vertex also announced the expansion of...

Simply Wall St 18h
Vertex Stock Looks Reasonable As Growth Must Justify Its Run

Vertex Pharmaceuticals has delivered strong long term gains over the past five years, yet current valuation checks suggest the stock now looks closer to fairly...

Vertex Stock Looks Reasonable As Growth Must Justify Its Run
TipRanks 4d
Crinetics Shareholders Approve Vertex Acquisition at Special Meeting

Crinetics Pharmaceuticals ( (CRNX) ) has provided an update. On August 28, 2026, Crinetics Pharmaceuticals shareholders held a special meeting at which approxi...

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
18.8%
Sell
6.3%

More VRTX News

TipRanks 4d
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors

Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Vertex’s new Phase 1 study, officially titled “A Phase 1, Open-label Dr...

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.